NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Review Proposals Project

NICE Technology Appraisal No.177; Alitretinoin for the treatment of chronic eczema of the hand, refractory to steroids

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors	General
Basilea Medical (alitretinoin)	Allied Health Professionals Federation
Daenea mearea (antrem)	Board of Community Health Councils in
Patient/carer groups	Wales
Action Against Allergy	British National Formulary
Afiya Trust	Care Quality Commission
Allergy UK	Commissioning Support Appraisals
Black Health Agency	Service
 Changing faces 	Department of Health, Social Services
Counsel and Care	and Public Safety for Northern Ireland
For all Control On the Control On th	Healthcare Improvement Scotland
 Equalities National Council Let's Face It 	Medicines and Healthcare products
M 11 0 11 (D 1)	Regulatory Agency
	 National Association of Primary Care
Muslim Health Network National Forema Society	National Pharmacy Association
National Eczema Society Skip Corp. Corp. pigs.	NHS Alliance
Skin Care Campaign	NII 10 0
South Asian Health Foundation	
Specialised Healthcare Alliance	NHS Confederation Public Health Wales NIJC Trust
Duefe e sieu el europa	Public Health Wales NHS Trust One and the second
Professional groups	Scottish Medicines Consortium
British Association for Services to the	Comparator manufacturar(a)
Elderly	Comparator manufacturer(s)
British Association of Dermatologists British Contact Paragettic Conjects	Actavis UK (azathioprine)
British Contact Dermatitis Society	Arrow Generics (azathioprine) Across Haldings Clabel (azathioprine)
British Dermatological Nursing Group	Aspen Holdings Global (azathioprine) Payer J. Pharma (circle an aria)
British Geriatrics Society	Dexcel-Pharma (ciclosporin) Olava Carith King (a path in pring)
British Skin Foundation	GlaxoSmithKline (azathioprine)
Primary Care Dermatology Society	Mylan UK(azathioprine, ciclosporin)
Royal College of General Practitioners	Novartis Pharmaceuticals (ciclosporin)
Royal College of Nursing	Sandoz (azathioprine)
Royal College of Pathologists	Sinclair Pharmaceuticals (azathioprine)
Royal College of Physicians	Teva UK (azathioprine)
Royal Pharmaceutical Society	
Royal Society of Medicine	Relevant research groups
United Kingdom Clinical Pharmacy	British Epidermo-Epidemiology Society
Association	Cochrane Skin Group

National Institute for Health and Clinical Excellence

NICE Technology Appraisal no.177; Alitretinoin for the treatment of eczema

Issue date: August 2012

Consultees	Commentators (no right to submit or appeal)
 Others Cheshire, Warrington and Wirral PCT Cluster Department of Health Tees PCT Cluster Welsh Government 	 MRC Clinical Trials Unit National Institute for Health Research Research Institute for the Care of Older People Skin Research Centre Skin Treatment & Research Trust Assessment Group Assessment Group tbc National Institute for Health Research Health Technology Assessment Programme
	Associated Guideline Groups National Clinical Guidelines Centre
	Associated Public Health Groups None

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD). All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.